TerminatedNot applicableNCT02835599
Official study title

Registry for the EVolution Of LUng Cancer Therapy Implementation and Outcomes Now

Study summary

REVOLUTION will be a US multicenter observational registry in scope and governed by a steering committee of approximately 8 experts in NSCLC and outcomes research. The primary goal of the registry is characterizing patterns of use for NSCLC therapy. REVOLUTION will be a multicenter registry enrolling approximately 2,500 patients. Additional patients limited to those with EGFR mutations may be enrolled following the initial study period as needed to ensure adequate sample sizes needed to examine primary questions of interest in the EGFR mutant population. Patients will be enrolled over a three year period across approximately 25 geographically diverse academic as well as community based sites within the US. The five year follow-up period will ensure robust survival data for correlations with clinical, tumor, and treatment variables. The target of 2,500 patients is meant to ensure adequate numbers of NSCLC patients with particular characteristics of interest including patients with adenocarcinoma, and EGFR mutations and effectively evaluate these patients with respect to key outcomes of interest including overall survival, time to progression, stage at progression, secondary metastases including brain metastases (at diagnosis and progression), comorbidity burden, and performance status at index date. The study design allows a cross-sectional perspective with collection of detailed patient and clinical characteristics at enrollment followed by longitudinal assessment of clinician and patient-reported endpoints every three months. Centralized follow-up will be conducted by having sites upload patient data following each visit via the web-based data system, with patients who do not show up for site visits being contacted via telephone by the Duke Clinical Research Institute (DCRI) call center. Site recruitment and patient enrollment will be weighted based upon provider specialty and ability to enroll patients with NSCLC with the specified inclusion criteria.

Ask AI to explain this study
Start here

Key things to know

Main goalNot specified

This describes the study’s primary purpose.

What is being studiedNot specified

The study team can explain what participation involves.

Who it may be forNon-small cell lung cancer (NSCLC) · EGFR

These are broad labels—not an eligibility decision.

Checked against the public recordLast updated Aug 22, 2017 · Source: ClinicalTrials.gov

Is enrollment open?Terminated

Ask the study team to confirm whether enrollment is open.

What kind of study?Not applicable

Observational

Where is it offered?15 U.S. locations

Locations may change over time.

Who runs it?AstraZeneca

Study sponsor

01
Study overview

What this study is about

Purpose
Not specified
Study type
Observational
Phase
Not applicable
Sponsor
AstraZeneca
Interventions being studied
Not specified
02
Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

03
Public criteria

Who may be able to participate

The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.

Requirements people may need to meetInclusion criteria

1. ≥19 years of age 2. Patients with a primary diagnosis of NSCLC within the past 5 years who are eligible for their first systemic therapy based on disease characteristics. Systemic therapy may include any cytotoxic, targeted, immune-based, or otherwise non-local treatment modality. Specific allowed settings include the following: 1. Incident metastatic disease (stage IV) undergoing palliative therapy 2. Non-metastatic disease undergoing adjuvant, neoadjuvant, or concurrent chemoradiation with either curative or palliative intent 3. Recurrent or subsequently metastatic disease (any stage) 3. Pathologic confirmation of malignancy prior to initiation of first systemic therapy 4. Submission of archival biospecimen sample(s) (collected up to two years prior) for analysis 5. Availability of key variables at the time of screening (e.g. stage, demographics) 6. Have been fully informed and are able to provide written consent for longitudinal follow-up and agree to be accessible by phone 7. Patients may be concurrently enrolled in unblinded clinical trials, but not blinded clinical trials in which the treatment being administered is unknown

Reasons someone may not be able to joinExclusion criteria

1. Pre-specified enrollment caps have been met (Figure 1) 2. Suspected recurrent or subsequently metastatic disease that is not biopsy confirmed prior to receipt of initial systemic therapy

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

04
Study sites

U.S. locations

  • Research SiteMonterey, California
  • Research SiteSanta Rosa, California
  • Research SiteColorado Springs, Colorado
  • Research SiteDenver, Colorado
  • Research SiteChicago, Illinois
  • Research SiteUrbana, Illinois
  • Research SiteSouthfield, Michigan
  • Research SiteDuluth, Minnesota
  • Research SiteRochester, Minnesota
  • Research SiteJackson, Mississippi
  • Research SiteOmaha, Nebraska
  • Research SiteRock Hill, South Carolina

Source and freshness
Processed from ClinicalTrials.gov. Last public update: Aug 22, 2017. Always confirm current availability with the study team.

View original record ↗